Schwab Charles Investment Management Inc. increased its position in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 17.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 224,352 shares of the biotechnology company’s stock after purchasing an additional 33,472 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.49% of Atara Biotherapeutics worth $8,245,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $107,000. Bank of Montreal Can purchased a new position in Atara Biotherapeutics during the second quarter valued at $180,000. Highland Private Wealth Management purchased a new position in Atara Biotherapeutics during the second quarter valued at $202,000. Principal Financial Group Inc. purchased a new position in Atara Biotherapeutics during the first quarter valued at $214,000. Finally, Amalgamated Bank purchased a new position in Atara Biotherapeutics during the second quarter valued at $228,000.

A number of research analysts have issued reports on ATRA shares. BidaskClub cut Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, August 3rd. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Finally, Citigroup lowered their price objective on Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating for the company in a research note on Monday, June 11th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $43.17.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction on Wednesday, September 19th. The stock was sold at an average price of $39.81, for a total value of $310,518.00. Following the completion of the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at approximately $32,350,123.53. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Christopher Haqq sold 31,500 shares of Atara Biotherapeutics stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $40.17, for a total value of $1,265,355.00. Following the completion of the sale, the executive vice president now directly owns 317,286 shares of the company’s stock, valued at approximately $12,745,378.62. The disclosure for this sale can be found here. In the last three months, insiders sold 142,675 shares of company stock valued at $5,593,522. Corporate insiders own 10.60% of the company’s stock.

Shares of NASDAQ:ATRA opened at $42.10 on Thursday. Atara Biotherapeutics Inc has a 12-month low of $12.65 and a 12-month high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.17). equities research analysts predict that Atara Biotherapeutics Inc will post -4.58 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.